Agilent Technologies will acquire Cartagenia, a provider of software and services for clinical genetics and molecular pathology labs.
The companies did not disclose the cost of the acquisition which is expected to be completed on May 19.
As a part of acquisition, Agilent, a test and measurement company, will provide employment to 36 employees of Cartagenia. Cartagenia provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays.
Company officials said technicians, lab directors and clinicians can visualize, assess and report clinical genetics data in the context of patient information with Cartagenia Bench platform. Cartagenia offers internal knowledge base, variant assessments SOPs, automate report drafting, and a range of community validated, private and premium content resources to the labs.
Additionally, Cartagenia’s platform also provides deep support for consortia of collaborating labs and allows user to connect and pool their knowledge on rare diseases and actionable findings.
In March, Cartagenia announced a partnership with Lexington, MA-based N-of-One, provider of patient-specific Clinical Interpretation for molecular profiles at the disease, gene and variant level.
In January, Cartagenia joined hands with MedGenome Inc, the developer of the OncoMD Cancer knowledge base.
Last month, Agilent collaborated with the National University of Singapore (NUS) Yong Loo Lin School of Medicine to help researchers develop more effective medicine to treat cardiovascular disease.
Agilent Technologies introduced the Agilent 6545 Q-TOF mass spectrometry system, designed to provide added sensitivity for routine analyses.